Drug
BBI-825
BBI-825 is a pharmaceutical drug with 2 clinical trials. Currently 1 active trials ongoing.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(50%)
Terminated
1(50%)
Phase Distribution
Ph phase_1
2
100%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Terminated(1)
Detailed Status
Active, not recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
0.0%
Most Advanced
Phase 1
Trials by Phase
Phase 12 (100.0%)
Trials by Status
active_not_recruiting150%
terminated150%
Recent Activity
1 active trials
Showing 2 of 2
active_not_recruitingphase_1
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
NCT05827614
terminatedphase_1
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
NCT06299761
Clinical Trials (2)
Showing 2 of 2 trials
NCT05827614Phase 1
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
NCT06299761Phase 1
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2